Market Place
Sourcing Support
All News #Library
Biotech
Merck, Rivals Eye Inhibrx Experimental Drug Tied to Keytruda
25 Apr 2026 //
REUTERS
Inhibrx Update on Ozekibart in Late Line Colorectal Cancer
23 Apr 2026 //
PR NEWSWIRE
Inhibrx Announces Participation In Upcoming Scientific Conference
02 Mar 2026 //
PR NEWSWIRE
Inhibrx Biosciences Updates INBRX-106 And Ozekibart Expansion
16 Dec 2025 //
PR NEWSWIRE
Inhibrx To Participate In Future Scientific Conferences
05 Nov 2025 //
PR NEWSWIRE
Inhibrx Report Positive Ozekibart Data, Shares Cancer Updates
24 Oct 2025 //
PR NEWSWIRE
Inhibrx to Present Ozekibart Data, Cancer Cohort Updates
23 Oct 2025 //
PR NEWSWIRE
Inhibrx Biosciences Announces CSO Departure and New Appointments
01 Apr 2025 //
PR NEWSWIRE
Inhibrx Reports 2024 Financial Results
17 Mar 2025 //
PR NEWSWIRE
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
24 May 2024 //
PR NEWSWIRE
Inhibrx Announces Sale of INBRX-101 to Sanofi for value of up to $2.2B
23 Jan 2024 //
PR NEWSWIRE
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109
02 Nov 2023 //
PR NEWSWIRE
Inhibrx Granted Fast Track for INBRX-101 for Alpha-1 Antitrypsin Deficiency
30 May 2023 //
PR NEWSWIRE
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD
26 Apr 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.